Description

Denosumab (Prolia) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Denosumab is a fully-human, immunoglobulin G1 (IgG2) mAb against RANKL that is in Phase III of development for RA patients with active, erosive bone disease. The Phase III clinical program is currently supported by Daiichi Sankyo for use in the Japanese population. Denosumab was once under investigation for RA by Amgen, which owns the rights to the molecule in the US and 5EU. However, a Phase II trial was completed in 2007, with no further development, and Amgen does not list denosumab for RA in its March 2014 pipeline on the companys webpage.

View Full Report at http://www.marketresearchreports.biz/analysis/247173

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Denosumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Denosumab for the top country from 2013 to 2023.
- Sales information covered for Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Denosumab performance.
- Obtain sales forecast for Denosumab from 2013-2023 in top country (Japan).

Download Detail Report With Complete TOC at
http://www.marketresearchreports.biz/sample/sample/247173

Table of Content

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 18
3.3 Prognosis 19
3.4 Quality of Life 19
4 Disease Management 20
4.1 Diagnosis and Treatment Overview 20
4.1.1 Diagnosis 20
4.1.2 Treatment Guidelines 22
4.1.3 Leading Prescribed Drugs for the Treatment of RA 32
4.1.4 Clinical Practice 34
5 Competitive Assessment 39
5.1 Overview 39
6 Unmet Need and Opportunity 41
6.1 Overview 41
6.2 Development of Cost-Effective Therapies 42
6.2.1 Unmet Need 42
6.2.2 Gap Analysis 43
6.2.3 Opportunity 43
6.3 Biomarkers to Predict Responsiveness to Therapy 44
6.3.1 Unmet Need 44
6.3.2 Gap Analysis 46
6.3.3 Opportunity 46
7 Pipeline Assessment 53
7.1 Overview 53
Browse Latest News at http://www.marketresearchreports.biz/articles

About Us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz